Private equity firm buys Tanzania’s generic drug maker Zenufa for undisclosed price

Catalyst Principal Partners, a private equity firm focused on East Africa, has picked up Zenufa Laboratories, Tanzania’s second-largest generic drug maker.

Terms of the deal weren’t disclosed.

Zenufa manufactures a wide range of over-the-counter and prescription medicines for the Tanzanian market, and was the first facility in the country to be  certified as 100% cGMP compliant.

Free Amazon Webinar

Performing end to end real-world evidence generation in the cloud with traceability and transparency- a Sanofi journey

In this webinar you will hear about Sanofi’s journey and experience in building an industrialized big data & analytics platform in the cloud that handles billions of rows of RWD data with complete data traceability, security, and supports both traditional and advanced analytics for day to day evidence generation (RWE).

“While the healthcare sector remains dominated by foreign imports representing majority of Tanzania’s medicine supply, as an established local pharmaceutical manufacturer, Zenufa is uniquely positioned to meet the rising healthcare needs of the population through offering affordable, quality medication manufactured to the highest international best practice standards,” Martha Osier, a Catalyst investment manager, said in a statement.

The Zenufa purchase represents Catalyst’s fourth investment in Tanzania and its second in the healthcare sector. It bought Mimosa Pharmacy in 2014, which now operates under the name “Goodlife Pharmacy” and is rapidly expanding its pharmacy retail business.

- here’s the release

Related Article:
Tanzania, like GlaxoSmithKline, learns delivery tricks from Coke

Suggested Articles

Biocon has finally satisfied the FDA that its insulin production plant in Malaysia is ready for prime time.

Nearly four decades after it was approved, the FDA has ordered that heartburn drug Zantac and its generics be removed from the market.

Pfizer's 1.1-million-square-foot sterile injectables plant in Visakhapatnam has been criticized by the FDA for poor quality testing.